AnaptysBio Inc (ANAB.OQ)
ANAB.OQ on NASDAQ Stock Exchange Global Select Market
91.67USD
20 Apr 2018
91.67USD
20 Apr 2018
Change (% chg)
$0.80 (+0.88%)
$0.80 (+0.88%)
Prev Close
$90.87
$90.87
Open
$90.39
$90.39
Day's High
$92.55
$92.55
Day's Low
$90.00
$90.00
Volume
91,314
91,314
Avg. Vol
143,381
143,381
52-wk High
$134.00
$134.00
52-wk Low
$18.18
$18.18
About
AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro,... (more)
Overall
| Beta: | -- |
| Market Cap(Mil.): | $725.82 |
| Shares Outstanding(Mil.): | 20.34 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| ANAB.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 84.02 | 32.74 |
| EPS (TTM): | -1.06 | -- | -- |
| ROI: | -23.31 | 1.58 | 14.38 |
| ROE: | -48.33 | 2.41 | 16.07 |
BRIEF-Anaptysbio Announces Positive Top-Line Proof-Of-Concept Data For ANB020 In Moderate-To-Severe Baseline Adult Peanut Allergy Patients
* ANAPTYSBIO ANNOUNCES POSITIVE TOP-LINE PROOF-OF-CONCEPT DATA FOR ANB020 IN MODERATE-TO-SEVERE BASELINE ADULT PEANUT ALLERGY PATIENTS
BRIEF-AnaptysBio Qtrly Loss Per Share $0.30
* ANAPTYSBIO ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND 2018 PIPELINE MILESTONES
BRIEF-Anaptysbio qtrly loss per share $0.45
* Anaptysbio announces third quarter 2017 financial results and provides pipeline updates
BRIEF-AnaptysBio reports positive ANB019 top-line phase 1 clinical trial results
* Anaptysbio reports positive anb019 top-line phase 1 clinical trial results
Competitors
| Price | Chg | |
|---|---|---|
| Roche Holding Ltd. (ROG.S) | CHF215.65 | -- |
| Roche Holding Ltd. (RO.S) | CHF220.00 | -- |
| GlaxoSmithKline plc (GSK.L) | 1,430.00 | -- |
| Teva Pharmaceutical Industries Limited (TEVA.TA) | 6,361.00 | +96.00 |
| Allergy Therapeutics plc (AGY.L) | 24.75 | 0.00 |
| AstraZeneca plc (AZN.L) | 4,976.00 | -- |
| Pfizer Inc. (PFE.N) | $36.63 | +0.10 |
| Regeneron Pharmaceuticals Inc (REGN.OQ) | $314.25 | -1.58 |
| Sanofi SA (SASY.PA) | €65.28 | -- |
| Amgen, Inc. (AMGN.OQ) | $171.56 | -1.37 |
Estimates